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Heart Failure
Effect of QRS Duration and Morphology on Cardiac
Resynchronization Therapy Outcomes in Mild Heart Failure
Results From the Resynchronization Reverses Remodeling in Systolic Left
Ventricular Dysfunction (REVERSE) Study
Michael R. Gold, MD, PhD; Christophe The´bault, MD; Cecilia Linde, MD, PhD;
William T. Abraham, MD; Bart Gerritse, PhD; Stefano Ghio, MD;
Martin St. John Sutton, MD, FRCP; Jean-Claude Daubert, MD
Background—Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces
reverse left ventricular remodeling in selected populations with heart failure. We aimed to assess the impact of
baseline QRS duration and morphology and the change in QRS duration with pacing on CRT outcomes in mild
heart failure.
Methods and Results—Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE)
was a multicenter randomized trial of CRT among 610 patients with mild heart failure. Baseline and CRT-paced QRS
durations and baseline QRS morphology were evaluated by blinded core laboratories. The mean baseline QRS duration
was 15123 milliseconds, and 60.5% of subjects had left bundle-branch block (LBBB). Patients with LBBB
experienced a 25.3-mL/m2 mean reduction in left ventricular end-systolic volume index (P0.0001), whereas
non-LBBB patients had smaller decreases (6.7 mL/m2; P0.18). Baseline QRS duration was also a strong predictor of
change in left ventricular end-systolic volume index with monotonic increases as QRS duration prolonged. Similarly,
the clinical composite score improved with CRT for LBBB subjects (odds ratio, 0.530; P0.0034) but not for
non-LBBB subjects (odds ratio, 0.724; P0.21). The association between clinical composite score and QRS duration
was highly significant (odds ratio, 0.831 for each 10-millisecond increase in QRS duration; P0.0001), with improved
response at longer QRS durations. The change in QRS duration with CRT pacing was not an independent predictor of
any outcomes after correction for baseline variables.
Conclusion—REVERSE demonstrated that LBBB and QRS prolongation are markers of reverse remodeling and clinical
benefit with CRT in mild heart failure.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271154.
(Circulation. 2012;126:822-829.)
Key Words: bundle-branch block  pacing  cardiomyopathy  heart failure
Cardiac resynchronization therapy (CRT) improves func-tional status and cardiac function and decreases heart
failure (HF) hospitalizations and mortality among HF patients
with left ventricular (LV) systolic dysfunction and QRS
prolongation.1– 8 Initially, CRT was applied to patients with
advanced HF, but more recent studies have shown similar
benefit among patients with milder HF.9 –11 Several studies
have demonstrated that the hemodynamic response, extent of
LV volumetric changes (ie, reverse remodeling), and clinical
outcomes are affected by baseline or CRT-paced ECG char-
acteristics.6,12–16 These studies suggest that patients with
longer intrinsic QRS duration, left bundle-branch block
(LBBB) morphology, and greater QRS shortening with
biventricular pacing have better outcomes. Conversely, those
with non-LBBB morphology do not benefit from or may even
worsen with CRT. However, a comprehensive evaluation of
QRS duration and morphology on structural and clinical
outcomes with CRT has not been performed previously.
Accordingly, the present analysis was designed to evaluate
the role of intrinsic and CRT-paced QRS characteristics on
CRT in the Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction (REVERSE) study.
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Methods
The design and primary results of the REVERSE trial were published
previously.9,17,18 Briefly, eligible patients had American College of
Cardiology/American Heart Association stage C or New York Heart
Association class I (previously symptomatic, currently asymptomatic)
or class II (mildly symptomatic) HF for at least 3 months before
enrollment. Patients were required to be in sinus rhythm with a
QRS duration 120 milliseconds, an ejection fraction 40%, and
an LV end-diastolic dimension 55 mm measured by transtho-
racic echocardiography. All patients were receiving optimal
medical therapy for HF, including stable doses of an angioten-
sin-converting enzyme inhibitor or angiotensin II receptor blocker
and a -blocker.19 Patients requiring pacing were excluded. The
ethics committee of each center approved the study protocol, and
all patients gave written informed consent.
All patients underwent implantation of a CRT system (device and
leads), with or without implantable cardioverter-defibrillator capa-
bilities, on the basis of standard clinical criteria. Patients who had
undergone successful implantation (n610) were then randomly
assigned in a 2:1 fashion to active CRT (CRT ON) or to a control
group (CRT OFF). By study design, patients were followed up in
their randomized arms for 12 months in North America and for 24
months in Europe. Those assigned to CRT ON were programmed to
simultaneous biventricular pacing in the DDD mode at a lower rate
of 35 bpm. Those patients randomized to CRT OFF were pro-
grammed to the DDI mode at a lower rate of 35 bpm.
Analyses were performed on 12-lead ECGs collected at baseline
and after successful CRT implantation but before randomization to
CRT ON or OFF by researchers at core laboratories who were
blinded to randomization assignment and clinical outcomes. Conse-
quently, patients had not received CRT before these measurements
were made. Intrinsic QRS morphology and duration were measured,
as well as CRT-paced QRS duration. Both intrinsic QRS duration
and paced QRS duration were measured on a tracer table as the mean
from 9 consecutive cycles in leads II, V1, and V6. The intraobserver
and interobserver reproducibilities were evaluated by a second
measurement of 50 randomly selected ECGs prepared by another
expert interpreter. The intraobserver and interobserver coefficients of
variability of the unpaced and paced QRS complexes were 1.6% and
1.4%, and 6.4% and 2.6%, respectively. Morphology was classified
as LBBB, right bundle-branch block (RBBB), or nonspecific intra-
ventricular conduction delay (IVCD) by World Health Organization
criteria.20,21 LBBB was thus defined as QRS duration 120 milli-
seconds; QS or rS in lead V1; broad R waves in leads I, aVL, V5, or
V6; and absent q waves in leads V5 and V6. For the purpose of the
present analyses, all other patients were combined as a non-LBBB
cohort. In addition, analyses were performed with the non-LBBB
cohort subdivided into subgroups of RBBB, IVCD, and narrow QRS
(120 milliseconds). In the overall study,9 each center interpreted
the ECG and baseline echocardiography independently of the core
laboratories to determine criteria for study entry, including QRS
duration. Of note, core laboratory evaluation of QRS data was
performed after enrollment; thus, some patients were classified as
narrow QRS even though study inclusion criteria specified a QRS
duration 120 milliseconds.
The primary end point of REVERSE was the clinical composite
score (CCS).17,22 Using this end point, we classified patients into 1 of
3 response groups: worsened, unchanged, or improved. Patients were
judged to be worsened if they died, were hospitalized for worsening
HF, crossed over to or permanently discontinued double-blind
treatment owing to worsening HF, or demonstrated worsening in
New York Heart Association class or moderate to marked worsening
of patient global assessment. Patients were judged to be improved if
they had not worsened and had demonstrated improvement in New
York Heart Association class and/or a moderate to marked improve-
ment in patient global assessment. Patients who were not worsened
or improved were classified as unchanged.
Echocardiograms were obtained at baseline and after 12 months of
randomization. Data were analyzed in 1 of 2 core laboratories by
researchers blinded to clinical data. LV dimensions were recorded
with 2-dimensional directed M-mode echocardiography at the tips of
the mitral valve leaflets. Echocardiograms were digitized to obtain
LV volumes by the Simpson method of disks, as recommended by
the American Society of Echocardiography,23 from which LV
ejection fraction was calculated. Change in LV end-systolic volume
indexed by body surface area (LVESVi) was the predefined and
independently powered secondary end point of REVERSE. Further
details of the echocardiographic protocol have been published
previously.24
Data Analysis
Continuous variables are summarized with mean and standard
deviation; categorical variables, with counts and percentages. Com-
parisons of baseline variables between patients with and without
LBBB use the Student t test and Fisher exact test. Outcome
parameters were analyzed with regression models that include some
or all of QRS duration, LBBB, and study arm, with interactions.
Effect estimates and P values were derived from contrasts. Interac-
tion P values are reported to assess the difference of the effect of
CRT between LBBB and non-LBBB. The CCS was analyzed as a
3-category ordinal variable by use of ordinal logistic regression. A
reported odds ratio 1 indicates improvement; ie, patients are less
likely to be in the worse categories. Echocardiographic parameters
were analyzed with linear regression. Time-to-event analyses used
Kaplan–Meier estimates and Cox proportional hazards regression to
compute hazard ratios and to assess influence of covariates. Survival
curves and rates were compared by the log-rank test. To assess
possible confounding by baseline characteristics that differ between
patients with and without LBBB, those characteristics with P0.10
were added to the models to observe qualitative changes in the
relation between outcome parameters and LBBB. The relation
between QRS duration and outcomes is graphically illustrated with
smooth curves fitted to the data using a cubic spline method. This
technique extends the standard fitting of straight regression lines and
finds a curve that optimally balances goodness of fit against minimal
curvature.25
The immediate QRS change is the difference between unpaced
baseline QRS and biventricular paced QRS measured before perma-
nent CRT programming. Normalized acute QRS change was calcu-
lated by subtracting the expected QRS change based on baseline
QRS as calculated from a linear regression model.
A value of P0.05 was considered statistically significant.
P values were not adjusted for multiple comparisons.
Results
Patient Population
All 610 patients randomized in REVERSE were included in
this analysis. Demographic and other characteristics of the
patient population are presented in Table 1. The mean age
was 62.511.0 years; 79% were male; and 55% had ischemic
heart disease as the primary cause of HF. The mean ejection
fraction was 26.77.0%. The intrinsic QRS duration could be
determined by the core laboratory for 582 patients and was
15123 milliseconds. QRS morphology could be determined
by the core laboratory for 593 patients. For 14 patients, the
classification by the investigator is used in analysis. For the
remaining 3 patients, QRS morphology remains unknown.
Table 1 also shows the patient characteristics grouped by
QRS morphology. There was no significant difference in the
proportion of patients in the CRT ON versus OFF groups
with LBBB (61.1% versus 59.2%, respectively). However,
there are some important differences between the groups.
Specifically, subjects with LBBB were less likely to be men,
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to have diabetes mellitus, or to have an ischemic type of HF.
The LBBB group also had significantly longer intrinsic QRS
duration with a mean of 159 milliseconds compared with 139
milliseconds in the non-LBBB group (P0.0001) and better
functional status as evidenced by quality-of-life scores and
6-minute hall-walk distances. The non-LBBB group con-
sisted of 57 patients with narrow QRS (120 milliseconds),
55 patients with RBBB, and 126 patients with IVCD.
Echocardiographic Changes
One of the hallmark findings of CRT is the reduction of LV
volumes and the increase in LV ejection fraction as part of the
reverse remodeling response. Paired baseline and 12-month
echocardiographic data were available for 509 patients, with
an overall LVESVi reduction of 18.328.9 mL/m2 in the
CRT ON arm. The results for change in LVESVi at 12
months grouped by QRS morphology are shown in Table 2.
There was a large reduction of LVESVi with CRT noted in
this study that was observed primarily in the LBBB cohort.
For the LBBB group, there was a 25.3-mL/m2 mean reduction
in LVESVi (P0.0001 versus CRT OFF), whereas in the
non-LBBB group, this decrease was much smaller and
nonsignificant (6.7 mL/m2; P0.18). LV end-diastolic vol-
ume index showed a similar relationship with QRS morphol-
ogy, as shown in Table 2. Finally, a significant increase in
ejection fraction was observed only in the LBBB cohort. Lack
of reverse remodeling is consistent among the non-LBBB
subgroups, with an LVESVi reduction of 6.6 mL/m2 in
patients with narrow QRS, 2.8 mL/m2 for RBBB, and 8.6
mL/m2 for IVCD. Model-based estimates for CRT effect are
shown in Table 3 with corresponding 95% confidence
intervals.
To evaluate the impact of QRS duration on remodeling
parameters, patients were divided into quartiles based on the
intrinsic QRS duration. The changes in LVESVi are shown in
Table 4. The reduction of LVESVi increased progressively
Table 1. Baseline Patient Characteristics
QRS Morphology*
All Patients
(n610)
LBBB
(n369)
Non-LBBB
(n238) P†
Age, y 62.511.0 62.311.3 63.010.3 0.42
Male, n (%) 479 (79) 266 (72) 210 (88) 0.0001
NYHA functional class II, n (%) 503 (82) 310 (84) 192 (81) 0.32
Ischemic, n (%) 333 (55) 160 (43) 173 (73) 0.0001
Diabetic, n (%) 137 (22) 66 (18) 71 (30) 0.001
Chronic obstructive pulmonary disease, n (%) 60 (10) 34 (9) 26 (11) 0.49
ACE inhibitors or ARBs, n (%) 590 (97) 359 (97) 228 (96) 0.36
-blockers, n (%) 580 (95) 351 (95) 226 (95) 1.00
Intrinsic QRS duration, ms 15123 15918 13923 0.0001
LV ejection fraction, % 26.77.0 26.67.0 26.77.2 0.88
LV end-diastolic dimension, cm 6.70.9 6.71.0 6.60.7 0.19
Interventricular mechanical delay, ms 33.639.0 47.633.7 11.836.6 0.0001
Minnesota Living With HF Score 27.620.6 26.219.1 29.722.7 0.055
6-min hall walk, m 395127 408122 374132 0.001
CRT-D implanted, n (%) 508 (83) 292 (79) 213 (89) 0.001
LBBB indicates left bundle-branch block; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker; LV, left ventricular; HF, heart failure, and CRT-D, cardiac resynchronization therapy
with implantable cardioverter-defibrillator capabilities.
*For 3 patients, QRS morphology could not be classified.
†P values are for LBBB vs non-LBBB patients.
Table 2. Effect of QRS Morphology on Changes in Echocardiographic Parameters at 12 Months
LBBB Non-LBBB
CRT OFF
(n99)
CRT ON
(n211) P
CRT OFF
(n66)
CRT ON
(n131) P
P for
Interaction*
LVESVi, mL/m2 1.725.8 25.328.5 0.0001 1.519.7 6.725.8 0.18 0.0003
LVEDVi, mL/m2 1.830.0 25.731.5 0.0001 1.224.7 8.530.5 0.11 0.0043
LVEF, % 0.86.9 6.99.7 0.0001 0.76.3 0.97.2 0.88 0.0002
LBBB indicates left bundle-branch block; CRT OFF, group with no cardiac resynchronization therapy; CRT ON, group
with cardiac resynchronization therapy; LVESVi, left ventricular end-systolic volume index; and LVEF, left ventricular
ejection fraction.
*Assesses the difference of CRT effect between LBBB and non-LBBB.
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with QRS prolongation in the presence of CRT (P0.0001),
with little change observed in the control population
(P0.87; P for interaction0.0001). Figure 1 illustrates the
continuous relationship between QRS duration and change in
LVESVi using spline smoothing. The relationship in the CRT
ON group is fairly linear and intersects the CRT OFF group
and a 0 change at a QRS duration of 120 milliseconds.
When subgrouped by QRS morphology, the relationship
between QRS duration and LVESVi noted above was due
primarily to the LBBB cohort. Specifically, there was an
estimated incremental decrease in LVESVi of 5.7 mL/m2 for
each 10-millisecond increase of the QRS duration by linear
regression analysis among LBBB subjects (P0.0001; Fig-
ure 2A). No significant relationship between QRS duration
and LVESVi was observed in the non-LBBB cohort (0.13
mL/m2; P0.20; Figure 2B). A similar interaction between
QRS duration and morphology was observed for LV end-di-
astolic volume index. Specifically, an estimated incremental
decrease in LV end-diastolic volume index of 6.1 mL/m2 for
each 10-millisecond increase in QRS duration was noted for
LBBB subjects (P0.0001), but no relationship between
QRS duration and these volumetric changes was observed for
non-LBBB subjects (0.39 mL/m2; P0.81).
Clinical Response
The primary end point for REVERSE was the CCS.9,17 The
results grouped by randomization and QRS morphology are
summarized in Table 5. In the control arm (CRT OFF), the
distribution of CCS was similar between the LBBB and
non-LBBB groups (P0.12). CRT had no significant effect
for the non-LBBB group (for CRT ON relative to CRT OFF:
odds ratio, 0.724; P0.21) but markedly improved the CCS
for the LBBB group (odds ratio, 0.530; P0.0034). However,
the odds ratios for non-LBBB and LBBB were not signifi-
cantly different (P for interaction0.35). Of note, the re-
sponse in the non-LBBB group was not homogeneous, with
improved CCS for RBBB patients (odds ratio, 0.272;
P0.014) but not for IVCD or narrow QRS. Odds ratio
estimates for all groups are provided in Table 3.
In addition to the CCS, we evaluated the commonly used
composite end point of time to first HF hospitalization or
all-cause death. In the LBBB group, the curves diverged early
and more end point events were observed in the CRT OFF
cohort (hazard ratio, 0.48; P0.028; Figure 3A). Event rates
were somewhat higher in the non-LBBB group and the curves
also seemed to diverge, but this difference did not reach
statistical significance (hazard ratio, 0.53; P0.081; Figure
3B). The hazard ratios for LBBB and non-LBBB are not
significantly different (P for interaction0.86). A significant
reduction of events was observed in RBBB patients (hazard
ratio, 0.083; P0.0032) but not in IVCD (hazard ratio, 0.60;
P0.31) or narrow QRS (hazard ratio, 2.21; P0.46; see also
Table 3).
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Figure 1. The absolute change in left ventricular end-systolic
volume index (LVESVi) at 12 months. Each point represents data
from 1 patient. The open symbols are for cardiac resynchroniza-
tion therapy on (CRT ON) patients; closed symbols, control
(CRT OFF) patients. The black line is the expected LVESVi
change using spline smoothing for the CRT ON group; the gray
line, the change for the CRT OFF group.
Table 3. Cardiac Resynchronization Therapy Effect Estimates by QRS Morphology
LBBB (n369)
Non-LBBB (n238)
RBBB (n55) IVCD (n126) Narrow QRS (n57) All
LVESVi change, mL/m2 23.7 (29.9 to 17.4) 3.5 (19.1 to 12.0) 7.8 (18.3 to 2.6) 0.5 (16.8 to 17.7) 5.2 (13.0 to 2.5)
LVEDVi change, mL/m2 23.9 (31.1 to 16.8) 4.5 (22.3 to 13.3) 10.5 (22.5 to 1.5) 0.3 (20.1 to 19.5) 7.3 (16.2 to 1.6)
LVEF change, % 6.0 (4.1 to 8.0) 0.2 (5.0 to 4.7) 0.8 (2.5 to 4.0) 0.5 (5.9 to 4.8) 0.2 (2.2 to 2.6)
CCS, odds ratio 0.53 (0.35 to 0.81) 0.27 (0.10 to 0.77) 0.79 (0.40 to 1.57) 1.42 (0.46 to 4.34) 0.72 (0.44 to 1.20)
Composite end point, HR 0.48 (0.24 to 0.94) 0.083 (0.01 to 0.69) 0.60 (0.22 to 1.65) 2.21 (0.27 to 18.0) 0.53 (0.26 to 1.09)
LBBB indicates left bundle-branch block; RBBB, right bundle-branch block; IVCD, intraventricular conduction delay; LVESVi, left ventricular end-systolic volume
index; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; CCS, clinical composite score; and HR, hazard ratio. Values in
parentheses are 95% confidence intervals.
Table 4. Effect of Intrinsic QRS Duration on Left Ventricular
End-Systolic Volume Index Change at 12 Months
QRS Duration, ms CRT OFF (n), ml/m2 CRT ON (n), ml/m2
134 1.417.5 (38) 5.220.5 (81)
134–152 3.520.7 (38) 12.326.1 (88)
152–167 7.721.9 (41) 23.032.2 (82)
168–218 2.927.1 (44) 33.329.2 (77)
All* 0.722.5 (161) 18.129.1 (328)
CRT OFF, group with no cardiac resynchronization therapy; CRT ON, group
with cardiac resynchronization therapy.
*Baseline QRS and paired echocardiographic data are available for 489
patients.
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The effect of QRS duration on CCS was also evaluated.
In the control arm (CRT OFF), there was no relationship
between CCS and QRS duration (odds ratio, 1.016 for each
10-millisecond increase in QRS duration; P0.79). How-
ever, in the CRT arm, the association between CCS and
QRS duration was highly significant (odds ratio, 0.831 for
each 10-millisecond increase in QRS duration; P0.0001),
with improved response at longer QRS durations. This
relationship is further illustrated in Figure 4. Spline
smoothing is used to plot the percentage of patients
improved (ie, responders) in relation to QRS duration for
the 2 randomized groups. There is little change in response
for the CRT OFF group, whereas the proportion of responders
increases as baseline QRS duration is prolonged in the CRT ON
group. The curves cross at a QRS duration of 115 millisec-
onds, suggesting a lack of benefit of CRT in patients with
narrow QRS.
The observed relations between outcome parameters and
LBBB were also present in multivariable models that in-
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Figure 2. The absolute change in left ventricular end-systolic
volume index (LVESVi) at 12 months. A, The left bundle-branch
block (LBBB) group; B, the non-LBBB group. Each point repre-
sents data from 1 patient. The open symbols are for cardiac
resynchronization therapy on (CRT ON) patients; the closed
symbols, control (CRT OFF) patients. The curved black line is
the expected LVESVi change using spline smoothing for the
CRT ON group; the curved gray line, the change for the CRT
OFF group. The straight black and gray lines are model-based
regression lines.
Table 5. Clinical Composite Score Grouped by Randomization
and QRS Morphology
LBBB (%) Non-LBBB (%)
CRT OFF CRT ON CRT OFF CRT ON
Improved 50 (44.2) 154 (60.2) 26 (33.3) 73 (45.6)
Unchanged 42 (37.2) 76 (29.7) 32 (41.0) 46 (28.8)
Worsened 21 (18.6) 26 (10.2) 20 (25.6) 41 (25.6)
Odds ratio 0.530 0.724
P 0.0034 0.21
LBBB indicates left bundle-branch block; CRT OFF, group with no cardiac resyn-
chronization therapy; and CRT ON, group with cardiac resynchronization therapy.
A
B
Figure 3. Kaplan–Meier curves showing time to the composite
end point of first heart failure (HF) hospitalization or all-cause
death. A, The left bundle-branch block (LBBB) group; B, the
non-LBBB group.
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cluded the baseline characteristics that differed between
patients with and without LBBB at P0.10.
Paced QRS Duration
The immediate change in QRS duration with pacing has been
reported to predict outcomes with CRT.14 To evaluate this
possibility in REVERSE, we analyzed the acute QRS change
in the CRT ON group. Acute QRS change was 626
milliseconds (LBBB, 1324 milliseconds; non-LBBB,
326 milliseconds). For the primary end point, the associa-
tion between CCS and acute QRS change is highly significant
(odds ratio, 0.877 for each 10-millisecond additional acute
decrease in QRS duration; P0.0011). To explore these
observations further, the relationship between unpaced base-
line QRS duration and acute QRS change was analyzed,
showing a moderate correlation (r0.46, P0.0001), and
normalized QRS change was calculated. In a multivariate
model for CCS with baseline QRS duration and normalized
acute QRS change as covariates, only baseline QRS was
significant (P0.0001 in CRT ON arm versus P0.20 for
normalized acute QRS change). Similar results were observed
with other end points. Specifically, the association between
LVESVi change and acute QRS change was highly signifi-
cant (P0.0001). However, in the multivariate model, only
baseline QRS was significant (P0.0001 versus P0.14 for
normalized acute QRS change). Finally, in the CRT ON arm,
the association between the incidence of death or HF hospi-
talization and acute QRS change was highly significant
(P0.0054), but only baseline QRS was significant
(P0.0002 versus P0.39 for normalized acute QRS
change) in the multivariate model.
Discussion
The primary results of this analysis suggest that the benefit of
CRT in mild HF is strongly dependent on QRS morphology
and duration. Specifically, echocardiographic changes in
volumes and ejection fraction were noted only in the LBBB
cohort, and the magnitude of this response was strongly
dependent on baseline QRS duration. Similarly, improvement
in the CCS with CRT was larger in the LBBB cohort, and
again it was related strongly to baseline QRS duration.
Finally, the change in QRS duration with pacing was not an
independent predictor of outcomes.
The results of the present study are consistent with several
previous studies of QRS morphology on CRT in both the
advanced and mild HF populations. Specifically, subgroup
analyses of multiple trials of New York Heart Association
class III/IV subjects showed minimal or no benefit in the
presence of RBBB.6,13,26 The results for REVERSE were
mixed with regard to response in RBBB subjects. The
echocardiographic measures of reverse remodeling were at-
tenuated and nonsignificant in this subgroup, although there
was an improvement in clinical outcomes. More recently,
Resynchronization-Defibrillation for Ambulatory Heart Fail-
ure Trial (RAFT)11 and the Multicenter Automatic Defibril-
lator Implantation Trial–Cardiac Resynchronization Therapy
(MADIT-CRT)16 evaluated the impact of QRS morphology
on clinical response and noted benefit only in the LBBB
subgroup, not in the composite of non-LBBB subjects.
The impact of QRS duration on outcomes has also been
evaluated previously in CRT trials. Most commonly, QRS
duration is dichotomized at 150 milliseconds for these anal-
yses, with a smaller or no response observed among subjects
with QRS duration 150 milliseconds.10,11 However, trans-
forming a continuous measure such as QRS duration into a
dichotomous one may not be optimal for analysis. Accord-
ingly, we subdivided the cohort into quartiles based on
unpaced QRS duration and analyzed outcomes with regres-
sion models that include QRS duration as a continuous
parameter.
We observed that the relationship between QRS duration
and response to CRT is best treated as a continuous variable,
with larger response rates as QRS is prolonged. Moreover,
the curve for change in LVESVi with CRT intercepts 0 at a
QRS duration of 120 milliseconds, and the curves for active
CRT and control for the CCS cross at 115 milliseconds.
These similar observations are intriguing and indicate a lack
of benefit among patients with narrow QRS, as shown in the
subgroup analyses of that cohort. This is consistent with other
multicenter studies of CRT specifically addressing this
issue.27,28
Although the change in QRS duration with biventricular
pacing was associated with clinical outcomes, this effect was
no longer significant in a multivariate model that corrected
for baseline QRS duration. These 2 parameters were corre-
lated. Thus, QRS duration tends to shorten more with longer
baseline QRS durations and may even be prolonged with
shorter baseline QRS durations. Accordingly, the change in
QRS duration with pacing reflects primarily the intrinsic QRS
duration. Although the total paced QRS duration was not an
independent predictor of response, we did not evaluate
whether other properties of the paced complex predicted
response, as reported recently.29
There are several clinical implications of these data. First,
CRT in mild HF patients may need to be restricted to those
with LBBB. Second, we found a progressive incremental
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Figure 4. Effect of unpaced QRS duration on the proportion of
patients with an improved clinical composite score. The curves
use spline smoothing and are for the cardiac resynchronization
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response to CRT by increasing QRS duration but with no
clear cutoff value for reverse remodeling or clinical benefit of
CRT other than the conventional cutoff of 120 milliseconds.
Thus, responses increase with increasing QRS prolongation
but, importantly, with no response for QRS durations 115
to 120 milliseconds. Accordingly, CRT should be avoided in
patients with narrow QRS, and the risks and benefits should
be weighed carefully among subjects with only modest QRS
prolongation or with non-LBBB morphology. Third, the
change in QRS duration with pacing did not independently
predict outcomes but rather was a reflection of intrinsic QRS
duration.
This study should be interpreted in the face of several
methodological limitations. First, randomization was not
stratified on the basis of QRS morphology or duration, and
many of these analyses were performed post hoc. Second, the
study was not powered to detect any clinically relevant
difference between QRS morphologies. Third, paired echo-
cardiographic data were incomplete. However, this did not
appear to affect the outcomes. The CCS is improved in 260 of
509 patients with complete echocardiographic data (51%) and
in 44 of 89 patients without complete echocardiographic data
who survived through 12 months (49%; P0.68). Moreover,
there is no observed difference in baseline LVESVi between
patients with (9938 mL/m2) and without (10337 mL/m2)
complete echocardiographic data (P0.51). Finally, this
study evaluated only subjects with mild HF, so the results
may not necessarily apply to patients with more severe HF.
Conclusions
In a large cohort of patients with QRS prolongation, LV
dilatation, but mild HF, CRT resulted in improved clinical
response, fewer HF hospitalizations, and greater reverse
remodeling. However, QRS morphology and duration had
important impacts on these end points. Specifically, little
remodeling or clinical benefit was observed in the absence of
LBBB. Additionally, both remodeling and clinical responses
increased progressively with increasing baseline QRS dura-
tion compared with little or no response in unpaced control
subjects or QRS durations 120 milliseconds.
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CLINICAL PERSPECTIVE
Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left
ventricular remodeling in selected populations with both mild and advanced heart failure. Despite these benefits of CRT,
nearly one third of subjects are typically classified as nonresponders. Characteristics of the surface ECG have been shown
to be important predictors of response in several previous studies. In the present analysis of the Resynchronization Reverses
Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial, the impact of baseline QRS duration and
morphology and the change in QRS duration with pacing on outcomes in mild heart failure with CRT were described.
Patients with left bundle-branch block experienced large reductions in left ventricular volumes, whereas patients with
non–left bundle-branch block had much smaller decreases. Baseline QRS duration was also a strong predictor of
remodeling, with monotonic increases as QRS duration prolonged and no obvious threshold above 120 milliseconds.
Similarly, clinical outcomes improved with CRT for left bundle-branch block subjects but not for non–left bundle-branch
block subjects, and clinical outcomes increased as QRS duration prolonged. The change in QRS duration with CRT pacing
was not an independent predictor of any outcomes after correction for baseline variables. These data indicate that left
bundle-branch block and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart
failure. However, the change in QRS duration with biventricular pacing is not a useful predictor of response independently
of the baseline ECG characteristics. Finally, despite the relationship between QRS duration and outcomes, these results do
not support the use of any arbitrary QRS duration cutoff 120 to 130 milliseconds for selecting CRT candidates.
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